These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 17090813)

  • 1. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Agarwal A; Vladutiu P; Feit A; Lapin R; Cavusoglu E
    J Invasive Cardiol; 2006 Nov; 18(11):521-6. PubMed ID: 17090813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Lazar J; Cavusoglu E
    Catheter Cardiovasc Interv; 2009 Feb; 73(2):214-21. PubMed ID: 19156882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
    J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
    Kini AS; Chen VH; Krishnan P; Lee P; Kim MC; Mares A; Suleman J; Moreno PR; Sharma SK
    Am Heart J; 2008 Sep; 156(3):513-9. PubMed ID: 18760134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bolus-only glycoprotein IIb/IIIa inhibitor revisited.
    Agahtehrani A; Dangas GD
    J Invasive Cardiol; 2006 Nov; 18(11):527. PubMed ID: 17090814
    [No Abstract]   [Full Text] [Related]  

  • 9. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
    Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
    Lincoff AM; Kleiman NS; Kereiakes DJ; Feit F; Bittl JA; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
    JAMA; 2004 Aug; 292(6):696-703. PubMed ID: 15304466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
    Akerblom A; James SK; Koutouzis M; Lagerqvist B; Stenestrand U; Svennblad B; Oldgren J
    J Am Coll Cardiol; 2010 Aug; 56(6):470-5. PubMed ID: 20670756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis.
    Lipinski MJ; Lee RC; Gaglia MA; Torguson R; Garcia-Garcia HM; Pichard AD; Satler LF; Waksman R
    Cardiovasc Revasc Med; 2016 Dec; 17(8):535-545. PubMed ID: 27842901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions.
    Deliargyris EN; Upadhya B; Applegate RJ; Kutcher MA; Gandhi SK; Sane DC
    J Invasive Cardiol; 2004 Nov; 16(11):611-6. PubMed ID: 15550727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
    Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).
    Singh HS; Dangas GD; Guagliumi G; Yu J; Witzenbichler B; Kornowski R; Grines C; Gersh B; Dudek D; Mehran R; Stone GW
    Am J Cardiol; 2012 Oct; 110(7):940-7. PubMed ID: 22748356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction.
    Raveendran G; Ting HH; Best PJ; Holmes DR; Lennon RJ; Singh M; Bell MR; Long KH; Rihal CS
    Mayo Clin Proc; 2007 Feb; 82(2):196-202. PubMed ID: 17290727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
    Kimmelstiel C; Phang R; Rehman A; Rand W; Miele R; Rhofiry J; MacIsaac DA; Gouveia W; Denier D; Becker RC
    J Thromb Thrombolysis; 2001 May; 11(3):203-9. PubMed ID: 11577258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: a meta-analysis of randomized trials.
    Pannu R; Andraws R
    Crit Pathw Cardiol; 2008 Mar; 7(1):5-10. PubMed ID: 18458661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.
    Cortese B; Micheli A; Picchi A; Bandinelli L; Brizi MG; Severi S; Limbruno U
    Coron Artery Dis; 2009 Aug; 20(5):348-53. PubMed ID: 19543084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.